Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Biological Therapy Année : 2021

Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE

Anna-Maria Henaine
  • Fonction : Auteur
Claude Dussart
Carl Counsell
  • Fonction : Auteur
Martin Connock
  • Fonction : Auteur

Dates et versions

hal-03368078 , version 1 (06-10-2021)

Identifiants

Citer

Xavier Armoiry, Hans-Martin Späth, Anna-Maria Henaine, Claude Dussart, Carl Counsell, et al.. Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE. Expert Opinion on Biological Therapy, 2021, 21, pp.741-747. ⟨10.1080/14712598.2021.1865305⟩. ⟨hal-03368078⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More